|
Bibliography
An asterisk (*) denotes an item that was particularly useful in the preparation of this issue of INFO Reports.
*1. ACCESS WORKING GROUP OF THE MICROBICIDE INITIATIVE. Preparing for microbicide access and use. New York, Rockefeller Foundation Microbicide Initiative, 2002. 38 p. (Available: <http://www.rockfound.org/Documents/488/rep6_preparing.pdf>, Accessed Oct. 20, 2004)
*2. ALLIANCE FOR MICROBICIDE DEVELOPMENT. Microbicide research and development database. (Available: <http://www.microbicide.org/>, Accessed Oct. 20, 2004)
3. ALLIANCE FOR MICROBICIDE DEVELOPMENT. Microbicides and clinical trials. 2 p. (Available: <http://www.microbicide.org/microbicideinfo/reference/clinical.trials.factsheet.pdf>, Accessed Aug. 31, 2004)
4. ANDERSON, R.A., FEATHERGILL, K.A., DIAO, X.H., COOPER, M.D., KIRKPATRICK, R., HEROLD, B.C., DONCEL, G.F., CHANY, C.J., WALLER, D.P., RENCHER, W.F., and ZANEVELD, L.J. Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. Journal of Andrology 23(3): 426-438. May-Jun. 2002.
5. ANDERSON, R.A., ZANEVELD, L.J., and USHER, T.C. Cellulose sulfate for use as antimicrobial and contraceptive agent inventors. US Patent 6,063,773. Polydex Pharmaceuticals, Ltd., Rush-Presbyterian-St. Luke's Medical Center, assignees, May 16, 2000.
6. BENTLEY, M.E., FULLEM, A.M., TOLLEY, E.E., KELLY, C.W., JOGELKAR, N., SRIRAK, N., MWAFULIRWA, L., KHUMALO-SAKUTUKWA, G., and CELENTANO, D.D. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. American Journal of Public Health 94(7): 1159-1164. Jul. 2004.
7. BENTLEY, M.E., MORROW, K.M., FULLEM, A., CHESNEY, M.A., HORTON, S.D., ROSENBERG, Z., and MAYER, K.H. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Family Planning Perspectives 32(4): 184-188. Jul.-Aug. 2000.
8. BHATTACHARYA, R. and SETH, R. Genesis of microbicides campaign in India [poster]. Presented at the Microbicides 2004 Conference, London, Mar. 28-31, 2004. (Available: <http://www.microbicides2004.org.uk/abstract/posters/c_02118.html>, Accessed Oct. 20, 2004)
9. BIOSYN INC. Biosyn, Inc. initiates phase 3 pivotal clinical trial with 1% C31G vaginal gel for prevention of HIV transmission. (Available: <http://www.biosyn-inc.com/PR05202004.html>, Accessed May 20, 2004)
10. BLANC, A.K. and WOLFF, B. Gender and decision-making over condom use in two districts in Uganda. African Journal of Reproductive Health 5(3): 15-28. Dec. 2001.
11. BOWCUT, J.C. Microbicide science and research update. Presented at the Global Campaign for Microbicides Pre-Conference, London, Mar. 28, 2004. Alliance for Microbicide Development. (Available: <http://66.148.1.123/clientfiles/Bowcut-ScienceAndResearchUpdate.ppt>, Accessed Oct. 20, 2004)
12. BRODY, S. and POTTERAT, J.J. Assessing the role of anal intercourse in the epidemiology of AIDS in Africa. International Journal of STD and AIDS 14(7): 431-436. Jul. 2003.
13. BROWN, H. Marvellous microbicides. Intravaginal gels could save millions of lives, but first someone has to prove that they work. Lancet 363(9414): 1042-1043. Mar. 27, 2004.
14. CARBALLO-DIEGUEZ, A., STEIN, Z., SAEZ, H., DOLEZAL, C., NIEVES-ROSA, L., and DIAZ, F. Frequent use of lubricants for anal sex among men who have sex with men: The HIV prevention potential of a microbicidal gel. American Journal of Public Health 90(7): 1117-1121. Jul. 2000.
15. COGGINS, C., BLANCHARD, K., and FRIEDLAND, B. Men's attitudes towards a potential vaginal microbicide in Zimbabwe, Mexico and the USA. Reproductive Health Matters 8(15): 132-141. May 2000.
16. COHEN, J., CACERES, F., and BEKSINSKA, M. Using conjoint analysis to measure design trade-offs for microbicide applicators. Presented at the Microbicides 2004 Conference, London, Mar. 28-31, 2004. PATH.
17. CONE, R.A. (Johns Hopkins University) [BufferGel] Personal communication, May 4, 2004.
*18. COPLAN, P.M., MITCHNICK, M., and ROSENBERG, Z.F. Regulatory challenges in microbicide development. Science 304(5679): 1911-1912. Jun. 25, 2004.
19. D'CRUZ, O.J. and UCKUN, F.M. Clinical development of microbicides for the prevention of HIV infection. Current Pharmaceutical Design 10(3): 315-336. 2004.
20. DOH, A., RODDY, R., NGAMPOUA, F., MCNEIL, L., NKELE, N., and LAI, J.J. Phase 1 multi-dose safety and acceptability study of 6% cellulose sulphate (CS). Presented at the Microbicides 2004 Conference, London, Mar. 28-31, 2004. (Available: <http://www.microbicides2004.org.uk/abstract/oral/b_02249.html>, Accessed Oct. 20, 2004)
21. DOUVILLE, K. (Biosyn) [Savvy] Personal communication, Aug. 31, 2004.
22. ENGENDERHEALTH, INTERNATIONAL PARTNERSHIP FOR MICROBICIDES, UNIVERSITY OF CAPE TOWN, and POPULATION COUNCIL. Paving the path: Preparing for microbicide introduction. 2004. (Available: <http://www.popcouncil.org/pdfs/paving.pdf>, Accessed Apr. 14, 2004)
23. ETTIEGNE-TRAORE, V., GHYS, P.D., VAN DAMME, L., N'KRUMAH, M., MAIGA, A., TIEMELE, A., MAH-BI, G., COULIBALY, I.M., LAGA, M., and GREENBERG, A.E. Acceptability and feasibility of a clinical trial to assess the efficacy of a microbicide-containing vaginal gel to prevent HIV infection among female sex workers in Abidjan, Cote d'Ivoire [letter]. AIDS 11(13): 1660-1662. Nov. 1997.
24. EUROPEAN CENTRE FOR THE EPIDEMIOLOGICAL MONITORING OF AIDS. Comparison of female to male and male to female transmission of HIV in 563 stable couples. European Study Group on Heterosexual Transmission of HIV. British Medical Journal 304(6830): 809-813. Mar. 28, 1992.
25. FELDBLUM, P.J. and FORTNEY, J.A. Condoms, spermicides, and the transmission of human immunodeficiency virus: A review of the literature. American Journal of Public Health 78(1): 52-54. Jan. 1988.
26. FLECK, F. Microbicides preventing HIV infection could be available by 2010. Bulletin of the World Health Organization 82(5): 393-394. May 2004. (Available: <http://www.scielosp.org/pdf/bwho/v82n5/v82n5a18.pdf>, Accessed Oct. 20, 2004)
27. FLEMING, T.R. and RICHARDSON, B.A. Some design issues in trials of microbicides for the prevention of HIV infection. Journal of Infectious Diseases 190(4): 666-674. Aug. 15, 2004.
28. FOSS, A.M., VICKERMAN, P.T., HEISE, L., and WATTS, C.H. Shifts in condom use following microbicide introduction: Should we be concerned? AIDS 17(8): 1227-1237. May 23, 2003.
29. FOWLER, K., KLASSE, P.J., and SATTENTAU, Q. Synergy between potential HIV microbicidal agents. Presented at the Microbicides 2004 Conference, London, Mar. 28-31, 2004. Sir William Dunn School of Pathology. (Available: <http://www.microbicides2004.org.uk/abstract/oral/a_02560.html>, Accessed Oct. 20, 2004)
30. GABELNICK, H. (CONRAD) [Estimates of microbicides costs and pricing] Personal communication, Aug. 23, 2004.
31. GABELNICK, H.L. and HARPER, M.J. The promise of public/private sector collaboration in the development of vaginal microbicides. International Journal of Gynaecology and Obstetrics 67 Suppl. 2: S31-38. Dec. 1999.
32. GARDNER, R., BLACKBURN, R., and UPADHYAY, U.D. Closing the condom gap. Population Reports, Series H, No. 9. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Apr. 1999. 36 p.
33. GLOBAL CAMPAIGN FOR MICROBICIDES. New microbicides trials in West Africa. Global Campaign News. Nov. 23, 2003. p. 3. (Available: <http://www.globalcampaign.org/clientfiles/GCnews28.pdf.pdf>, Accessed Apr. 9, 2004)
34. GREEN, G., POOL, R., HARRISON, S., HART, G.J., WILKINSON, J., NYANZI, S., and WHITWORTH, J.A. Female control of sexuality: Illusion or reality? Use of vaginal products in south west Uganda. Social Science and Medicine 52(4): 585-598. Feb. 2001.
35. GROSS, M. HIV topical microbicides: Steer the ship or run aground. American Journal of Public Health 94(7): 1085-1089. Jul. 2004.
36. HALPERIN, D.T. Heterosexual anal intercourse: Prevalence, cultural factors, and HIV infection and other health risks, part I. AIDS Patient Care and STDs 13(12): 717-730. Dec. 1999.
37. HARDY, E., DE PADUA, K.S., HEBLING, E.M., OSIS, M.J., and ZANEVELD, L.J. Women's preferences for vaginal antimicrobial contraceptives V. Attitudes of Brazilian women to the insertion of vaginal products. Contraception 67(5): 391-395. May 2003.
38. HARDY, E., DE PADUA, K.S., JIMENEZ, A.L., and ZANEVELD, L.J. Women's preferences for vaginal antimicrobial contraceptives I. Methodology. Contraception 58(4): 233-238. Oct. 1998.
39. HARDY, E., DE PADUA, K.S., JIMENEZ, A.L., and ZANEVELD, L.J. Women's preferences for vaginal antimicrobial contraceptives II. Preferred characteristics according to women's age and socioeconomic status. Contraception 58(4): 239-244. Oct. 1998.
40. HARDY, E., DE PADUA, K.S., OSIS, M.J., JIMENEZ, A.L., and ZANEVELD, L.J. Women's preferences for vaginal antimicrobial contraceptives IV. Attributes of a formulation that would protect from STD/AIDS. Contraception 58(4): 251-255. Oct. 1998.
41. HARDY, E., JIMENEZ, A.L., DE PADUA, K.S., and ZANEVELD, L.J. Women's preferences for vaginal antimicrobial contraceptives III. Choice of a formulation, applicator, and packaging. Contraception 58(4): 245-249. Oct. 1998.
42. HARRISON, P. [Microbicide development] Personal communication, Jun. 7, 2004.
43. HARRISON, P.F. Microbicide research and development: Where are we, where are we going, and how. Presented at the USAID Global Health Mini-University, Washington, DC, May 12, 2003. Alliance for Microbicide Development. (Available: <http://www.maqweb.org/miniu/present/Mircobicides.ppt>, Accessed: Oct. 20, 2004)
44. HARRISON, P.F., ROSENBERG, Z., and BOWCUT, J. Topical microbicides for disease prevention: Status and challenges. Clinical Infectious Diseases 36(10): 1290-1294. May 15, 2003.
45. HARVEY, S.M., BIRD, S.T., and BRANCH, M.R. A new look at an old method: The diaphragm. Perspectives on Sexual and Reproductive Health 35(6): 270-273. Nov.-Dec. 2003.
46. HARWELL, J.I., MOENCH, T., MAYER, K.H., CHAPMAN, S., RODRIGUEZ, I., and CU-UVIN, S. A pilot study of treatment of bacterial vaginosis with a buffering vaginal microbicide. Journal of Women's Health 12(3): 255-259. Apr. 2003.
47. HEALTH AND DEVELOPMENT NETWORKS. Microbicides this week: Launch $22 million microbicides research programme. (Available: <http://archives.healthdev.net/genderaids/msg00113.html>, Accessed Mar. 18, 2004)
48. HEISE, L. Topical microbicides: Missing link for HIV prevention. Sexual Health Exchange (1): 3-5. 1999.
49. HEISE, L. Responding to frequently asked questions. Global campaign for microbicides. 29 p. (Available: <http://www.global-campaign.org/clientfiles/pre-conferenceheise.pdf>, Accessed Oct. 20, 2004)
50. HEISE, L., ELLSBERG, M., and GOTTEMOELLER, M. Ending violence against women. Population Reports, Series L, No. 11. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Sep. 1999.
51. HEISE, L.L., MCGRORY, C.E., and WOOD, S.Y. Practical and ethical dilemmas in the clinical testing of microbicides: A report on a symposium. [Based on a symposium sponsored by Women's Health Advocates on Microbicides and the Population Council]. Takoma Park, Maryland, Center for Health and Gender Equity, 1998. 79 p.
52. HILL, R., RYAN, J., STONE, A., and FRANSEN, L. Vaginal microbicides for the prevention of HIV/AIDS: Assessment of the potential market. International Journal of Pharmaceutical Medicine 14(5): 271-278. Oct. 2000.
53. IRWIN, K., SCARLETT, M., and MOSELEY, R. The urgent need for new HIV/STD prevention options for women. Observations from the CDC. Journal of Women's Health 7(9): 1081-1086. Nov. 1998.
54. JEWKES, R.K., LEVIN, J.B., and PENN-KEKANA, L.A. Gender inequalities, intimate partner violence and HIV preventive practices: Findings of a South African cross-sectional study. Social Science and Medicine 56(1): 125-134. Jan. 2003.
55. JHA, A. Taking prevention of AIDS beyond ABC. Guardian. (London), Mar. 22, 2004.
56. JOHANSSON, E.D.B., MAGUIRE, R.A., and PHILLIPS, D.M. Pushing the frontiers of science: The Population Council's microbicide basic science network on vaginal microbicide research. International Journal of Gynecology and Obstetrics 67(2): S117-S124. Dec. 1999.
57. JUDSON, F.N., EHRET, J.M., BODIN, G.F., LEVIN, M.J., and RIETMEIJER, C.A. In vitro evaluations of condoms with and without nonoxynol 9 as physical and chemical barriers against chlamydia trachomatis, herpes simplex virus type 2, and human immunodeficiency virus. Sexually Transmitted Diseases 16(2): 51-56. Apr.-Jun. 1989.
58. KARMON, E., POTTS, M., and GETZ, W.M. Microbicides and HIV: Help or hindrance? Journal of Acquired Immune Deficiency Syndromes 34(1): 71-75. Sep. 1, 2003.
59. KILMARX, P., WANKRAIROJ, M., ACHALAPONG, J., BLANCHARD, K., CHAIKUMMAO, S., CONNOLLY, C., FRIEDLAND, B., and TAPPERO, J. Safety of Carraguard use by heterosexual men in a six month clinical trial in Thailand. Presented at the Microbicides 2004 Conference, London, Mar. 28-31, 2004. (Available: <http://www.microbicides2004.org.uk/abstract/oral/b_02676_1.html>, Accessed Oct. 20, 2004)
60. KREBS, F.C., MILLER, S.R., CATALONE, B.J., WELSH, P.A., MALAMUD, D., HOWETT, M.K., and WIGDAHL, B. Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: Comparative sensitivity of primary human vaginal keratinocytes. Antimicrobial Agents and Chemotherapy 44(7): 1954-1960. Jul. 2000.
61. KREISS, J., NGUGI, E., HOLMES, K., NDINYA-ACHOLA, J., WAIYAKI, P., ROBERTS, P.L., RUMINJO, I., SAJABI, R., KIMATA, J., FLEMING, T.R., ANZALA, A., HOLTON, D., and PLUMMER, F. Efficacy of nonoxynol-9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. Journal of the American Medical Association 268(4): 477-482. Jul. 22-29, 1992.
62. KUMARANAYAKE, L., WATTS, C., TERRIS-PRESTHOLT, F., VICKERMAN, P., and HEISE, L. Projections of the resource requirements for promoting and distributing microbicides. Presented at the Microbicides 2004 Conference, London, Mar. 28-31, 2004. (Available: <http://www.microbicides2004.org.uk/abstract/oral/c_02696.html>, Accessed Oct. 20, 2004)
63. LAMPHEAR, T., DES VIGNES, F., HARRISON, P., and BOWCUT, J. Determining the cost: Getting to proof of concept. Presented at the Microbicides 2004 Conference, London, Mar. 28-31, 2004. (Available: <http://www.microbicides2004.org.uk/abstract/oral/c_02406.html>, Accessed Oct. 20, 2004)
64. LISKIN, L., BLACKBURN, R., and MAIER, J.H. AIDS: A public health crisis. Population Reports, Series L, No. 6. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Jul.-Aug. 1986.
65. MAHMOUD, E.A., SVENSSON, L.O., OLSSON, S.E., and MARDH, P.A. Antichlamydial activity of vaginal secretion. American Journal of Obstetrics and Gynecology 172: 1268-1272. Apr. 1995.
66. MALONZA, I., MIREMBE, F., NAKABIITO, C., ODUSOGA, O.L., OSINUPEBI, O.A., KAMAL, H., CHITLANGE, S., ALI, M.M., HAZELDEN, C.N., LANDOULSI, S.B., CALLAHAN, M., FARLEY, T.M.M., and VAN DAMME, L. Expanded phase I safety and acceptability trial of 6% cellulose sulphate gel as a vaginal microbicide. Presented at the Microbicides 2004 Conference, London, Mar. 28-31, 2004. (Available: <http://www.microbicides2004.org.uk/abstract/posters/b_02597.html>, Accessed Oct. 20, 2004)
*67. MANTELL, J.E., MYER, L., CARBALLO-DIÉGUEZ, A., STEIN, Z., RAMJEE, G., MORAR, N.S., and HARRISON, P.F. Microbicide acceptability research: Current approaches and future directions. Social Science and Medicine. 2005. (forthcoming)
68. MASON, T.H., FOSTER, S.E., FINLINSON, H.A., MORROW, K.M., ROSEN, R., VINING, S., JOANIS, C.L., HAMMETT, T.M., and SEAGE, G.R., 3RD. Perspectives related to the potential use of vaginal microbicides among drug-involved women: Focus groups in three cities in the United States and Puerto Rico. AIDS and Behavior 7(4): 339-351. Dec. 2003.
69. MAUCK, C., WEINER, D., CREININ, M., BARNHART, K., CALLAHAN, M., and BAX, R. A phase I comparative post-coital testing and safety study of three concentrations of C31G. Presented at the Microbicides 2002 Conference, Antwerp, Belgium, May 12-15, 2002. (Available: <http://www.itg.be/micro2002/downloads/presentations/2Monday_May_13_2002/Track_B_sessions/Christine_Mauck.pdf>, Accessed Oct. 20, 2004)
70. MAUCK, C., FREZIERES, R., WALSH, T., ROBERGEAU, K., and CALLAHAN, M. Cellulose sulfate: Tolerance and acceptability of penile application. Contraception 64(6): 377-381. Dec. 2001.
71. MAUCK, C., ROSENBERG, Z., and VAN DAMME, L. Recommendations for the clinical development of topical microbicides: An update. AIDS 15(7): 857-868. May 4, 2001.
72. MAUCK, C., WEINER, D.H., BALLAGH, S., CREININ, M., ARCHER, D.F., SCHWARTZ, J., PYMAR, H., LAI, J.J., and CALLAHAN, M. Single and multiple exposure tolerance study of cellulose sulfate gel: A phase I safety and colposcopy study. Contraception 64(6): 383-391. Dec. 2001.
73. MAUCK, C.K., CREININ, M.D., BARNHART, K.T., BALLAGH, S.A., ARCHER, D.F., CALLAHAN, M.M., SCHMITZ, S.W., and BAX, R. A phase I comparative postcoital testing study of three concentrations of C31G. Contraception 70(3): 227-231. Sep. 2004.
74. MAUCK, C.K., FREZIERES, R.G., WALSH, T.L., SCHMITZ, S.W., CALLAHAN, M.M., and BAX, R. Male tolerance study of 1% C31G. Contraception 70(3): 221-225. Sep. 2004.
75. MAUCK, C.K., WEINER, D.H., CREININ, M.D., BARNHART, K.T., CALLAHAN, M.M., and BAX, R. A randomized phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II. Contraception 70(3): 233-240. Sep. 2004.
76. MAYER, K., PEIPERT, J., FLEMING, T., FULLEM, A., MOENCH, T., CU-UVIN, S., BENTLEY, M., CHESNEY, M., and ROSENBERG, Z. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clinical Infectious Diseases 32: 476-482. 2001.
77. MAYER, K.H., KARIM, S.A., KELLY, C., MASLANKOWSKI, L., REES, H., PROFY, A.T., DAY, J., WELCH, J., and ROSENBERG, Z. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 17(3): 321-329. Feb. 14, 2003.
78. MEDICAL RESEARCH COUNCIL and IMPERIAL COLLEGE LONDON. MDP Statement on Emmelle (dextrin-2-sulphate). London, Issued on behalf of the Microbicides Development Programme (MDP), Sep. 24, 2004.
79. MICROBICIDES DEVELOPMENT PROGRAMME. Clinical trial sites. (Available: <http://www.mdp.mrc.ac.uk/clinical.html>, Accessed Oct. 20, 2004)
80. MILSTIEN, J. and BELGHARBI, L. Regulatory pathways for vaccines for developing countries. Bulletin of the World Health Organization 82(2): 128-133. Feb. 2004.
81. MISHKIN, A.A. The economics of microbicide development. Presented at the Microbicides 2002 Conference, Antwerpen, Belgium, May 12-14, 2002. The Boston Consulting Group. (Available: <http://www.itg.be/micro2002/downloads/presentations/3Tuesday_May_14_2002/Track_C_sessions/Arnon_Mishkin.pdf>, Accessed Oct. 20, 2004)
82. MOENCH, T.R., CHIPATO, T., and PADIAN, N.S. Preventing disease by protecting the cervix: The unexplored promise of internal vaginal barrier devices. AIDS 15(13): 1595-1602. Sep. 2001.
83. MORROW, K., ROSEN, R., RICHTER, L., EMANS, A., FORBES, A., DAY, J., MORAR, N., MASLANKOWSKI, L., PROFY, A.T., KELLY, C., ABDOOL KARIM, S.S., and MAYER, K.H. The acceptability of an investigational vaginal microbicide, PRO 2000 gel, among women in a phase I clinical trial. Journal of Women's Health 12(7): 655-666. Sep. 2003.
84. NICOLOSI, A., CORREA LEITE, M.L., MUSICCO, M., ARICI, C., GAVAZZENI, G., and LAZZARIN, A. The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: A study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology 5(6): 570-575. Nov. 1994.
85. NYBLADE, L., PANDE, R., MATHUR, S., MACQUARRIE, K., KIDD, R., BANTEYERGA, H., KIDANU, A., KILONZO, G., MBWAMBO, J., and BOND, V. Disentangling HIV and AIDS stigma in Ethiopia, Tanzania and Zambia. International Center for Research on Women and the CHANGE Project, 2003. 62 p.
86. OLMSTED, S.S., DUBIN, N.H., CONE, R.A., and MOENCH, T.R. The rate at which human sperm are immobilized and killed by mild activity. Fertility and Sterility 73(4): 687-693. Apr. 2000.
87. PADIAN, N.S., SHIBOSKI, S.C., GLASS, S.O., and VITTINGHOFF, E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: Results from a ten-year study. American Journal of Epidemiology 146(4): 350-357. Aug. 15, 1997.
88. PEROTTI, M.E., PIROVANO, A., and PHILLIPS, D.M. Carrageenan formulation prevents macrophage trafficking from vagina: Implications for microbicide development. Biology of Reproduction 69(3): 933-939. Sep. 2003.
*89. PHARMACO-ECONOMICS WORKING GROUP OF THE MICROBICIDE INITIATIVE. The economics of microbicide development: A case for investment. New York, Rockefeller Foundation Microbicide Initiative, 2002. 27 p. (Available: <http://www.rockfound.org/Documents/488/rep3_economics.pdf>, Accessed Oct. 20, 2004)
90. PINKERTON, S.D. and ABRAMSON, P.R. Effectiveness of condoms in preventing HIV transmission. Social Science and Medicine 44(9): 1303-1312. May 1997.
91. POLYDEX PHARMACEUTICALS LIMITED. CONRAD's development plan for Ushercell moves forward in clinical trials. [Polydex Phamaceuticals Ltd. Press Release]. Jun. 24, 2003. (Available: <http://www.polydex.com/v2/news/03-06-24.html>, Accessed Oct. 20, 2004)
92. POPULATION COUNCIL. Carraguard: A microbicide in development. (Available: <http://www.popcouncil.org/pdfs/Carraguard.pdf>, Accessed Mar. 2004)
93. POPULATION COUNCIL. Clinical testing of candidate microbicides. (Available: <http://www.popcouncil.org/biomed/candidate.html>, Accessed Apr. 7, 2004)
*94. POPULATION COUNCIL and INTERNATIONAL FAMILY HEALTH. The case for microbicides: A global priority. 2nd ed. New York, Population Council and International Family Health, Jun. 2001. 28 p.
95. POTTS, M. [Microbicides research and development] Personal communication, May 3, 2004.
96. PROFY, A.T. (Indevus Pharmaceuticals, Inc.) [Pro 2000] Personal communication, Aug. 2004.
*97. PUBLIC HEALTH WORKING GROUP OF THE MICROBICIDE INITIATIVE. The public health benefits of microbicides in lower-income countries: Model projections. New York, The Rockefeller Foundation Microbicide Initiative, 2002. 58 p. (Available: <http://www.rockfound.org/Documents/488/rep7_publichealth.pdf>, Accessed Oct. 20, 2004)
98. RAMJEE, G., GOUWS, E., ANDREWS, A., MYER, L., and WEBER, A. The acceptability of a vaginal microbicide among South African men. International Family Planning Perspectives 27(4): 164-170. Dec. 2001.
99. RAMJEE, G., MORAR, N.S., ALARY, M., MUKENGE-TSHIBAKA, L., VUYLSTEKE, B., ETTIEGNE-TRAORE, V., CHANDEYING, V., KARIM, S.A., and VAN DAMME, L. Challenges in the conduct of vaginal microbicide effectiveness trials in the developing world. AIDS 14(16): 2553-2557. Nov. 10, 2000.
100. REANEY, P. Human trials of new anti-HIV gels announced. Reuters news service. (London), Mar. 23, 2004.
101. RODDY, R.E., CORDERO, M., CORDERO, C., and FORTNEY, J. A dosing study of nonoxynol-9 and genital irritation. International Journal of STD and AIDS 4(3): 165-170. May-Jun. 1993.
102. RODDY, R.E., SCHULZ, K.F., and CATES, W., JR. Microbicides, meta-analysis, and the N-9 question. Where's the research? [editorial]. Sexually Transmitted Diseases 25(3): 151-153. Mar. 1998.
103. ROMERO, J.F., THORN, M., and PHILLIPS, D. PC-815, a novel combination microbicide. Presented at the Microbicides 2004 Conference, London, Mar. 28-31, 2004. Population Council. (Available: <http://www.microbicides2004.org.uk/abstract/posters/a_02446.html>, Accessed Oct. 20, 2004)
104. ROSENTHAL, S.L., COHEN, S.S., and STANBERRY, L.R. Topical microbicides: Current status and research considerations for adolescent girls. Sexually Transmitted Diseases 25(7): 368-377.
Aug. 1998.
105. SCHWARTZ, J., MAUCK, C., LAI, J., ARCHER, D., BRACHE, V., CREININ, M., HILLIER, S., FICHOROVA, R., LINTON, K., and CALLAHAN, M. Phase I 14-day safety and acceptability study of cellulose sulphate. Presented at the Microbicides 2004 Conference, London, Mar. 28-31, 2004. (Available: <http://www.microbicides2004.org.uk/abstract/posters/b_02496.html>, Accessed Oct. 20, 2004)
*106. SCIENCE WORKING GROUP OF THE MICROBICIDE INITIATIVE. The science of microbicides: Accelerating development. New York, The Rockefeller Foundation Microbicide Initiative, 2002. 94 p. (Available: <http://www.rockfound.org/Documents/488/rep4_science.pdf>, Accessed Oct. 20, 2004)
107. SHIH, A. (Gates Foundation) [Gates Foundation microbicide grants] Personal communication, Aug. 10, 2004.
*108. SPIELER, J. (USAID) [Microbicides research and development] Personal communication, May 11, 2004.
109. SPIELER, J. and CLAYPOOL, L. Women take 'cides against AIDS: Microbicide update. Presented at the MAQ Mini-University, Washington DC, May 10, 2004. USAID. (Available: <http://www.maqweb.org/miniu/present/2004/Microbicides-J.Spieler-L.Claypool.ppt>, Accessed Oct. 20, 2004)
*110. STONE, A. Microbicides: A new approach to preventing HIV and other sexually transmitted infections. Nature Reviews Drug Discovery. 1(12): 977-985. Dec. 2002.
111. STONE, A. (International Working Group on Microbicides) [Obstacles to microbicide development] Personal communication, Jun. 7, 2004.
112. STONE, A.B. Clinical trials of microbicides. Microbicide Quarterly, Vol. 1 2003. p. 13-18. (Available: <http://www.microbicide.org/microbicideinfo/reference/final.TMQ.jul.aug.sep.2003.pdf>, Accessed Oct. 20, 2004)
113. STONE, K.M., GRIMES, D.A., and MAGDER, L.S. Personal protection against sexually transmitted diseases. American Journal of Obstetrics and Gynecology 155(1): 180-188. Jul 1986.
114. TABET, S.R., CALLAHAN, M.M., MAUCK, C.K., GAI, F., COLETTI, A.S., PROFY, A.T., MOENCH, T.R., SOTO-TORRES, L.E., POINDEXTER, I.A., FREZIERES, R.G., WALSH, T.L., KELLY, C.W., RICHARDSON, B.A., VAN DAMME, L., and CELUM, C.L. Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 gel: 3 randomized trials in healthy low-risk men and HIV-positive men. Journal of Acquired Immune Deficiency Syndromes 33(4): 476-483. Aug. 1, 2003.
115. TALLIS, V. Building community mobilization for microbicides: The time is now [poster]. Presented at the Microbicides 2004 Conference, London, Mar. 28-31, 2004. (Available: <http://www.microbicides2004.org.uk/abstract/posters/c_02418.html>, Accessed Oct. 20, 2004)
116. UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT (USAID). Report to Congress. US Agency for International Development's Microbicide and Vaccine Research Program. [unpublished]. Washington, DC, Jul. 2003. 12 p. (Available: <http://www.dec.org/pdf_ docs/PDABY330.pdf>, Accessed Oct. 20, 2004)
117. VAIL, J.G., COHEN, J.A., and KELLY, K.L. Improving topical microbicide applicators for use in resource-poor settings. American Journal of Public Health 94(7): 1089-1092. Jul. 2004.
118. VAN DAMME, L. Phase III clinical trials. Presented at the Microbicides 2004 Conference, London, Mar. 28-31, 2004. CONRAD. (Available: <http://www.gmp.org/micro2004/LutPrsnt.pdf>, Accessed Oct. 20, 2004)
119. VAN DAMME, L. (CONRAD) [Surfactants] Personal communication, Aug. 2004.
120. VAN DAMME, L., RAMJEE, G., ALARY, M., VUYLSTEKE, B., CHANDEYING, V., REES, H., SIRIVONGRANGSON, P., MUKENGE-TSHIBAKA, L., ETTIEGNE-TRAORE, V., UAHEOWITCHAI, C., KARIM, S.S., MASSE, B., PERRIENS, J., and LAGA, M. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet 360(9338): 971-977. Sep. 28, 2002.
121. VAN DAMME, L., WRIGHT, A., DEPRAETERE, K., ROSENSTEIN, I., VANDERSMISSEN, V., POULTER, L., MCKINLAY, M., VAN DYCK, E., WEBER, J., PROFY, A., LAGA, M., and KITCHEN, V. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sexually Transmitted Infections 76(2): 126-130. Apr. 2000.
122. VAN DE WIJGERT, J., FULLEM, A., KELLY, C., MEHENDALE, S., RUGPAO, S., KUMWENDA, N., CHIRENJO, Z., JOSHI, S., TAHA, T., PADIAN, N., BOLLINGER, R., and NELSON, K. Phase 1 trial of the topical microbicide BufferGel: Safety results from four international sites. AIDS 26(1): 21-27. Jan. 2001.
123. WILKINSON, D., THOLANDI, M., RAMJEE, G., and RUTHERFORD, G.W. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: Systematic review and meta-analysis of randomised controlled trials including more than 5000 women. The Lancet Infectious Diseases 2(10): 613-617. Oct. 2002.
124. WITHERELL, G.W. Glyminox Biosyn. Current Opinion in Investigational Drugs 5(2): 222-231. Feb. 2004.
*125. WOODSONG, C. Covert use of topical microbicides: Implications for acceptability and use. International Family Planning Perspectives 30(2): 94-98. Jun. 2004.
126. WORLD HEALTH ORGANIZATION (WHO). WHO/CONRAD technical consultation on Nonoxynol-9. Oct. 9-10, 2001. [Summary Report]. Geneva, 2003. 29 p. (Available: <http://www.who.int/reproductive-health/publications/rhr_03_8/n9.pdf>, Accessed Feb. 23, 2004)
127. ZEITLIN, L., HOEN, T., ACHILLES, S., HEGARTY, T., JERSE, A., KREIDER, J., OLMSTED, S., WHALEY, K., CONE, R., and MOENCH, T. Tests of BufferGel for contraception and prevention of sexually transmitted diseases in animal models. Sexually Transmitted Diseases 28(7): 417–423. Jul. 2001.
128. ZEITLIN, L. and WHALEY, K.J. Microbicides for preventing transmission of genital herpes. Herpes 9(1): 4-9. Apr. 2002.
Photo/illustration credits:
index.shtml: Jefferson Jackson Steele
microbs2.shtml: Population Council
microbs3.shtml: Frank Herholdt/Medical Research Council/Microbicides Development Programme
microbs3.shtml#a: Alliance for Microbicide Development
microbs4.shtml: Program for Appropriate Technology in Health
|
